Vet Pathol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akiyoshi, T.
Right arrow Articles by Tateyama, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akiyoshi, T.
Right arrow Articles by Tateyama, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Vet Pathol 41:154-163 (2004)
© 2004 American College of Veterinary Pathologists

Expression of Bone Morphogenetic Protein–6 and Bone Morphogenetic Protein Receptors in Myoepithelial Cells of Canine Mammary Gland Tumors

T. Akiyoshi, K. Uchida and S. Tateyama

Department of Veterinary Pathology, Faculty of Agriculture, Miyazaki University, Miyazaki, Japan


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
To study the ectopic chondrogenesis in canine mammary mixed tumors, the expression of bone morphogenetic protein–6 (BMP-6) and specific BMP receptors (BMPRs), BMPR-IA, BMPR-IB, and BMPR-II, was examined using immunohistochemical and immunoblot analysis in 39 canine mammary gland tumors. Immunohistochemically, BMP-6 and all three types of BMPRs were coexpressed in the myoepithelial cells and chondrocytes in six of eight benign mixed tumors. In complex adenomas, myoepithelial cells showed an expression pattern of BMP-6, BMPR-IA, and BMPR-II similar to those in benign mixed tumors, whereas immunoreactivity for BMPR-IB was very mild. The myoepithelial cells proliferating within the basement membrane showed more intense immunoreactivity for BMP-6 and all BMPRs as compared with those proliferating in the interstitial areas. Western blotting analysis revealed immunopositive bands at 40–45 kDa for BMP-6 in the samples from simple and complex adenomas and benign mixed tumors. The BMPR-IB–specific bands at 45 kDa were most detected in benign mixed tumors. Because among BMPRs, BMPR-IB is thought to be the major receptor for BMP-6 for primary chondrogenesis, these findings suggest that the expression of BMP and its receptors on the myoepithelial cells might play a role in the ectopic cartilage formation in canine mammary gland tumors, especially in benign mixed tumors.

Key words: BMP-6; BMPR; dogs; mammary tumor; myoepithelial cells.

Mammary gland tumors are the most common tumors in female dogs.22 These tumors have various histologic features that are characterized by complex proliferation of abundant myoepithelial cells, mesenchymal components such as cartilage, bone, and bone marrow, or both. The tumors accompanied by the proliferation of myoepithelial cells are classified as complex tumors, and the tumors containing mesenchymal tissues, such as cartilage and bone, together with the proliferation of myoepithelial cells are called mixed tumors. The morphologic features of these canine mammary tumors are in conformity with those of human salivary and mammary pleomorphic adenomas at the point of ectopic mesenchymal tissue formation.7

Recent studies of human salivary gland pleomorphic adenomas indicate that bone morphogenetic proteins (BMPs) participate in their morphologic pleomorphism.10,17,18 BMPs are multifunctional proteins originally isolated from bone and are identified by their ability to induce ectopic cartilage and bone formation.1,16 BMPs regulate various aspects of organogenesis during development13,23 and osteogenesis.24 These proteins also have been detected in various mesenchymal and epithelial tumors, and they participate in ectopic ossification or epithelial-mesenchymal interaction.9,10,16–18,29,34,35 It has been found that type IV collagen is important for the actions of BMPs because some types of BMPs, such as BMP-2 and BMP-7, can intimately bind to type IV collagen.8,25 BMP-2 coexisting with type IV collagen induces psammoma bodies in human ovarian cancer.15

BMP-6 was originally isolated from murine embryonic complementary deoxyribonucleic acid library.20 BMP-6 messenger ribonucleic acid (mRNA) and its protein were expressed in the suprabasal layer of skin, hypertrophic chondrocytes at endochondral ossification sites, and the central nervous system in vivo.13,20,32 BMP-6 induced differentiations of osteoblastic cell lines and keratinocytes in vitro5,6,11 and was detected in human neoplastic epithelial cells including breast, salivary, rectal, and thyroid carcinomas.2,9 It has been suggested that BMP-6 inhibits cell division, promotes cell differentiation, induces ectopic bone formation, or regulates epithelial-mesenchymal interaction (or all).2,5,17,32

BMPs transduce their effects through binding to two different types of serine-threonine kinase receptors, similar to other members of the transforming growth factor (TGF)-ß superfamily. Both type I and II receptors are required for signaling. BMPs including BMP-6 can bind to three type I receptors, BMP type IA receptor (BMPR-IA), BMPR-IB, and Activin type I receptor (ActR-I), and three type II receptors, BMPR-II, ActR-II, and ActR-IIB.33 BMPR-IA and BMPR-IB are structurally similar to each other but show distinct spatial and temporal expression patterns during bone formation and organogenesis.4,12,37 BMPR-IA is strongly expressed in prehypertrophic chondrocytes, osteoblasts, and periosteum in skeletal structures, although the expression of BMPR-IB is not detectable or detected at a low level in these sites. On the other hand, BMPR-IB is expressed in precartilaginous mesenchymal condensations and perichondrium at higher levels than BMPR-IA. The expression of BMPR-IB is predominantly detected in epithelial cells in various organs of the embryo, although both mesenchymal and epithelial cells express BMPR-IA in the same sites. It is considered that BMPR-II, like other type II receptors for the TGF-ß superfamily, acts as the primary ligand-binding receptor and produces phosphorylation of type I receptors, which is essential for downstream signal transduction.19,27 BMPR-II has been detected in osteogenic cells and lung epithelial cell lines in vitro and in the developing central nervous systems, adult rat brains, and ossification sites in vivo.27,28,33 BMP type I and II receptors also are detected in some tumors including human osteosarcomas and prostate carcinomas.14,21

A recent study of canine mammary gland tumors indicates that BMP-6 is expressed in mammary gland tumor cells, especially myoepithelial cells and ectopic cartilage of benign mixed tumors.30 This study is performed to evaluate whether BMP-6 functions as an essential factor for ectopic cartilage and bone formation using immunohistochemical methods for staining BMP-6 and its specific receptors, including BMPR-IA, -IB, and -II.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Tissue preparation

Thirty-nine mammary tumors from 32 dogs were studied. Fresh tissue samples were stored at -80 C. For diagnosis and immunohistochemical study, specimens were fixed in methanol-Carnoy's solution. Paraffin sections, 4 µm thick, were made and stained with hematoxylin and eosin for histopathologic diagnoses based on the World Health Organization classification.22 Briefly, 39 mammary tumors were classified into simple adenomas (n = 5), complex adenomas (n = 11), benign mixed tumors (n = 8), simple adenocarcinomas (n = 10), complex adenomas (n = 3), and carcinoma or sarcoma in mixed tumor (n = 2).

Immunohistochemistry

Goat antisera against human BMP-6 (1 : 20, Santa Cruz, Santa Cruz, CA), BMPR-IA (1 : 10, Santa Cruz), BMPR-IB (1 : 20, Santa Cruz), and BMPR-II (1 : 10, Santa Cruz) were used as primary antibodies. Immunostaining was performed using a system kit of avidin–biotin–peroxidase complex (ABC, PK4000, Vector Laboratories, Burlingame, CA). The sections were treated with methanol containing 0.5% hydrogen peroxide for 10 minutes at room temperature to block endogenous peroxidase. Slides were incubated with phosphate-buffered saline (PBS) (pH 7.4) containing 3% bovine serum albumin for 60 minutes at 37 C to avoid nonspecific binding. Then, the sections were incubated with appropriate concentrations of primary antibodies for 45 minutes at 37 C, followed by incubation with biotinylated rabbit serum against goat immunoglobulin G (Dako-Japan, Kyoto, Japan) and ABC reagent for 30 minutes at 37 C. The specimens were washed with PBS three times for 10 minutes after each step. For visualization, 3,3'-diaminobenzidine tetrachloride (DAB, Sigma, St. Louis, MO) was used. The slides were counterstained with hematoxylin. According to previous reports,3,31 mammary cells were classified into four cell types: 1) glandular epithelial cells, 2) resting and proliferating myoepithelial cells within the basement membrane, 3) spindle- and star-shaped myoepithelial cells proliferating in the interstitial areas, and 4) chondrocytes of ectopic cartilage. The immunohistochemical results were evaluated for each of the four cell types using semiquantitative analysis as follows: -, 0% positive cells; +, less than 10% positive cells; ++, 10–50% positive cells; and +++, more than 50% positive cells.

Western blotting

Frozen samples were washed and divided into two pieces. These were homogenized with sample buffer for BMP (0.5 M Tris-HCl, pH 6.8, 10% glycerol, and 2% sodium dodecyl sulfate [SDS]) or with sample buffer for BMPRs (0.01 M Tris-HCl, pH 8.0, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM iodoacetamide, 0.2 mg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.14 M NaCl, and 0.025% NaN3) at 4 C, as in previous reports.35,36 After centrifugation at 1,000 rpm for 5 minutes, insoluble debris was removed, and another sample buffer (0.13 M Tris-HCl, pH 6.8, 4% SDS, 10% 2-mercaptoethanol, and 14% glycerol) was added. Samples were boiled for 5 minutes, loaded on 10–20% SDS-polyacrylamide gels (ATTO, Tokyo, Japan), and transferred to polyvinylidene difluoride membranes (clearblot P, ATTO). After the transfer, membranes were incubated with 3% bovine serum albumin for 60 minutes at 37 C. Then, these were incubated with appropriate antibodies for 45 minutes at 37 C, followed by incubation with secondary antibody and ABC reagent for 30 minutes at 37 C. The membranes were washed with PBS-0.1% Tween three times for 10 minutes after each step. After washing with PBS for 10 minutes, immunoreactive bands were visualized using DAB.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Immunohistochemistry

The immunoreactivity for BMP and its receptors varied in foci within tumors examined. The results of typical foci in each mammary tumor and intact region are summarized in Tables 1–3.


View this table:
[in this window]
[in a new window]
  		Table 1. Immunoreactivity for BMP-6 and BMPRs in 24 benign mammary gland tumors.*.

 

View this table:
[in this window]
[in a new window]
  		Table 3. Immunoreactivity for BMP-6 and BMPRs in normal mammary tissue adjacent to 18 benign mammary tumors.*.

 
Simple adenomas (n = 5). The tumors were composed of well-differentiated glandular epithelial cells with resting myoepithelial cells. Proliferation of myoepithelial cells in either the ducts or interstitial areas was not evident. Immunoreactivity for BMP-6 and all three BMPRs was found in the glandular epithelial cells of one dog and in the resting myoepithelial cells of four dogs (Table 1). The immunoreactivity for BMPRs was found on the cell membrane. Although the number and distribution pattern of positive cells for BMP-6 and BMPRs varied in each of the five dogs, resting myoepithelial cells were most intensely positive for BMP-6 and BMPRs. The immunoreactivity for BMPR-IA and BMPR-II tended to coexist in these myoepithelial cells. BMPR-IB immunoreactivity was not always found in BMPR-IA–and BMPR-II–positive areas, but frequently localized in the BMP-6–positive glands.

Complex adenomas (n = 11). The tumors consisted of mixed proliferation of glandular and myoepithelial cells. The foci of myoepithelial proliferation sometimes extended to the interstitial area. The myoepithelial cells proliferating within the glands or tubules could be distinguished as resting or proliferating myoepithelial cells. The morphology of resting myoepithelial cells was very similar to that of normal cells. The proliferative myoepithelial cells formed distinct foci within the glands or tubules. The myoepithelial cells proliferating in the interstitial areas could be divided into spindle- and star-shaped cells. Spindle-shaped myoepithelial cells proliferated in the interstitial areas forming solitary foci. These cells had distinct eosinophilic to clear cytoplasm. On the other hand, the interstitial foci consisting of proliferating star-shaped cells had abundant mucinous stroma, occasionally accompanied by hyaline or chondroid changes. Immunoreactivity for BMP-6 was most intense in proliferating myoepithelial cells within the tubules (Fig. 1A). Star-shaped myoepithelial cells with hyaline or chondroid stroma also showed intense immunoreactivity for BMP-6. Spindle- and star-shaped myoepithelial cells without these chondroid changes exhibited very mild immunoreactivity for BMP-6, despite moderate BMP-6 reactivity of myoepithelial cells within the adjacent tubules. Regarding BMP type I receptors, myoepithelial cells within the tubules showed intense immunoreactivity for BMPR-IA (eight dogs) and BMPR-IB (three dogs, Table 1). Figure 1B–D shows a focus containing BMPR-IA–and BMPR-II–positive (Fig. 1B, D) and BMPR-IB–negative (Fig. 1C) myoepithelial cells within the tubules of dog No. 8. Interstitial myoepithelial cells tended to exhibit very mild immunoreactivity for all three BMPRs, as for BMP-6, although myoepithelial cells in the adjacent tubules showed moderate reactivity for all BMPRs. Proliferating myoepithelial cells in the interstitial areas showed no immunoreactivity for BMPR-IB except for one dog (Table 1).



View larger version (137K):
[in this window]
[in a new window]
  		Fig. 1. Mammary gland, complex adenoma; dog No. 8. Expression of BMP-6 and BMPRs in proliferative myoepithelial cells. The absence of immunoreactivity for BMPR-IB was due to variable expression in different areas of the tumor. Immunostaining for BMP-6 (A, +), BMPR-IA (B, +), BMPR-IB (C, -), or BMPR-II (D, +). See Table 1 for explanation of + and -. Bar = 30 µm.
Fig. 2. Mammary gland, benign mixed tumor; dog No. 19. Expression of BMP-6 and BMPRs in myoepithelial cells with chondroid change. Note the coexpression of BMP-6 and BMPRs in myoepithelial cells with chondroid stroma. Immunostainings for BMP-6 (A, +), BMPR-IA (B, +, arrows), BMPR-IB (C, -), or BMPR-II (D, +, arrows). See Table 1 for explanation of + and -. Bar = 40 µm.
Fig. 3. Mammary gland, benign mixed tumor; dog No. 22. Expression of BMP-6 and BMPRs in immature chondrocytes within incomplete cartilage (Fig. 3A–D) and mature chondrocytes within complete cartilage (Fig. E–H). Note the different immunoreactivity for BMPRs. Immunostaining for BMP-6 (A, + and E, +), BMPR-IA (B, - and F, +), BMPR-IB (C, - and G, +), or BMPR-II (D, +, arrows and H, +). See Table 1 for explanation of + and -. Bar = 30 µm.
Fig. 4. Mammary gland, simple adenocarcinoma; dog No. 33. Expression of BMPRs in tubular epithelial cells with squamous metaplasia. Squamous tubular epithelial cells are positive for BMPR-IB and BMPR-II. Immunostaining for BMPR-IB (A) or BMPR-II (B). See Table 1 for explanation of + and -. Bar = 30 µm.

 
Benign mixed tumors (n = 8). These tumors had ectopic cartilage formation, together with abundant proliferation of both myoepithelial and glandular epithelial cells. Two of eight dogs also had additional endochondral ossification. In six dogs, proliferating myoepithelial cells within the tubules were commonly immunoreactive for BMP-6 and all the BMPRs, whereas the intensity of staining varied (Table 1). Spindle- and star-shaped myoepithelial cells in the interstitial area also were positive for BMP-6 and all three BMPRs in these six dogs, although the intensity was weaker than that of intraductal myoepithelial cells. Star-shaped myoepithelial cells with chondroid stroma exhibited immunoreactivity for both BMP-6 (Fig. 2A) and BMPRs. Figure 2A–D represents a focus containing BMP-6–, BMPR-IA–, and BMPR-II–positive and BMPR-IB–negative star-shaped myoepithelial cells in dog No. 19. Myoepithelial cells adjacent to the ectopic cartilage also were moderately positive for BMP-6 and all BMPRs. Tubular epithelial cells in these areas were positive for BMPR-IA or BMPR-IB (or both). The cells, considered as immature chondrocytes within the rough irregular cartilage, exhibited very mild immunoreactivity for BMP-6 and BMPRs (Fig. 3A, D). In some foci, immunoreactivity for BMPRs, such as BMPR-IA and BMPR-IB, was absent (Fig. 3B, C). Mature chondrocytes within the complete cartilage were frequently immunoreactive for BMP-6 and for all BMPRs (Fig. 3E, H). Small tubular epithelial cells adjacent to immature cartilage were positive for BMP-6.

Simple adenocarcinomas (n = 10). These tumors were composed of a pure proliferation of poorly differentiated tubular and glandular epithelial cells. Four dogs had no myoepithelial component. The immunohistochemical results are summarized in Table 2. In only one dog, resting myoepithelial cells were weakly positive for BMP-6. Immunoreactivity for BMPR-IA was not detectable in either glandular epithelial or myoepithelial cells. In the foci with squamous cell metaplasia, coexpression of BMPR-IB and BMPR-II was observed in three dogs (Fig. 4A, B).


View this table:
[in this window]
[in a new window]
  		Table 2. Immunoreactivity for BMP-6 and BMPRs in 15 malignant mammary gland tumors.*.

 
Complex adenocarcinomas (n = 3). The morphologic features of these tumors were in conformity with those of complex adenomas, whereas epithelial or myoepithelial cells (or both) exhibited cellular atypia and invasive activity. The myoepithelial cells within the tubules were positive to varying degrees for BMP-6 in three dogs. Weak immunoreactivity for BMPR-IA was found in the glandular epithelial cells and myoepithelial cells within the tubules in two dogs. Glandular epithelial cells were positive for BMPR-IB in three dogs in various intensities. Myoepithelial cells within the tubules, especially proliferative cells, showed moderate to intense BMPR-IB expression in two dogs. The myoepithelial cells proliferating in the interstitial areas were negative for BMPR-IB. Mild to moderate BMPR-II immunoreactivity was found in the glandular epithelial cells in two dogs and in interstitial myoepithelial cells of one dog. BMP-6 and all three BMPRs were colocalized in glandular epithelial cells and myoepithelial cells within the tubule in one dog.

Adenocarcinoma in benign mixed tumor (n = 1). Briefly, the tumor had similar morphologic features to a benign mixed tumor, whereas the epithelial component had malignant features. The glandular epithelial and myoepithelial cells showed marked proliferation. Necrotic foci were evident around the mature cartilage. Intraductal and interstitial myoepithelial cells coexpressed BMP-6 and all three BMPRs. BMPR-IB and BMPR-II were also detected in glandular epithelial cells with squamous metaplasia.

Osteosarcoma in benign mixed tumor (n = 1). This tumor was composed of an irregular proliferation of spindle-shaped osteoblastic cells with distinct osteoid and chondroid stroma, together with the characteristic features of mixed tumors. Hypertrophic chondrocytes were moderately positive for BMP-6 and BMPR-IA and were weakly positive for BMPR-II. Immunoreactivity for BMPR-IB was found in immature chondrocytes. Resting myoepithelial cells adjacent to the neoplastic foci showed weak immunoreactivity for all BMPRs but not for BMP-6.

Normal mammary gland tissues (n = 18). Immunoreactivity for BMP-6 and BMPRs in intact mammary tissue around the benign tumors was examined. Immunohistochemical findings are summarized in Table 3. Among normal mammary glands adjacent to simple adenomas (n = 5), complex adenomas (n = 6), and benign mixed tumors (n = 7), immunoreactivity for BMP-6 and BMPRs was most frequently detected in those of benign mixed tumors (five of seven dogs). In normal mammary glands adjacent to simple adenomas (n = 5), only one dog had coexpression of BMP-6 and BMPR-IB in resting myoepithelial cells. In two of five dogs, there were no immunoreactive cells for BMP-6 and BMPRs (Table 3). Resting myoepithelial cells of intact glands around complex adenomas (n = 6) were weakly immunoreactive for BMP-6 and BMPR-IA in only one of six dogs. Resting myoepithelial or glandular epithelial cells (or both) in normal glands within benign mixed tumors showed coexpression of BMP-6 and all three BMPRs in two dogs.

Western blotting

Specific immunoreactive bands for BMP-6 at 40–45 kDa were detected in samples from benign mixed tumors, complex adenomas, and simple adenomas (Fig. 5). In the sample from adenocarcinoma in a benign mixed tumor, no immunoreactive bands were detectable. In the homogenates from two benign mixed tumors, there were specific immunoreactive bands for BMPR-IB at 45 kDa, but the reactivity for BMPR-IA and BMPR-II was weak or not detectable (Fig. 6). In one sample from a simple adenoma, the immunoblot pattern was similar to that in a benign mixed tumor. In complex adenomas, there was very weak immunoreactive band for BMPR-IB at 45 kDa.



View larger version (65K):
[in this window]
[in a new window]
  		Fig. 5. Western blotting analysis for BMP-6. MW, molecular weight markers; lanes 1 and 2, benign mixed tumor; lane 3, adenocarcinoma in benign mixed tumor; lane 4, complex adenoma; lanes 5 and 6, simple adenoma. Note the immunopositive bands at 40–45 kDa (lanes 1, 2, 4, and 5) for BMP-6.
Fig. 6. Western blotting analysis for BMPRs. MW, molecular weight markers; lanes 1–3, benign mixed tumor; lanes 4–6, complex adenoma; lanes 7–9, simple adenoma. Lanes 1, 4, and 7, BMPR-IA; lanes 2, 5, 8, BMPR-IB; lanes 3, 6, 9, BMPR-II. Note the immunoreactive bands (lanes 2, 5, and 8) for BMPR-IB at 45 kDa. Specific bands for BMPR-IA and BMPR-II were weak or undetectable.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In this study, coexpression of BMP-6 and BMPRs has been confirmed predominantly in the myoepithelial cells in several types of canine mammary gland tumors. The findings, together with our previous report,30 emphasized that myoepithelial cells expressing BMP-6 and BMPRs might play an important role for ectopic cartilage formation in canine mammary gland tumors. Expression of BMPR-IB, but not BMPR-IA, has been found in the early cartilage primordium of chick limb and in the perichondrium of developing cartilage of mice embryo.12,37 During later chondrogenesis, BMPR-IA and BMPR-IB are coexpressed in chondrocytes and osteoblasts. These results suggest that BMPR-IB is involved in the differentiation of immature mesenchymal cells into primordial chondrocytes and that BMPR-IA regulates later chondrogenesis. This study revealed the absence of BMPR-IB expression in spindle- and star-shaped myoepithelial cells of most complex adenomas (7 of 11 dogs). In contrast, most benign mixed tumors (six of eight dogs) had moderate immunoreactivity for BMPR-IB. The data may suggest a role for BMPR-IB in metaplastic change of myoepithelial cells into chondrocyte lineage. A limited number of complex adenomas (4 of 11 dogs) with BMPR-IB expression in myoepithelial cells might indicate incipient formation of cartilage and bone by myoepithelial metaplasia in these tumors. Proliferative myoepithelial cells within the basement membrane and interstitial myoepithelial cells of complex adenomas and benign mixed tumors were immunoreactive for BMPR-IA. Because BMPR-IA tended to be coexpressed with BMP-IB in both tumors, corroborative function of these two BMPRs are suggested for chondroid metaplasia in canine mammary tumors. BMPR-II also was detected in various types of myoepithelial cells of all mammary tumors examined. BMPR-II was not always coexpressed with BMPR-IB. Several previous studies showed that other type II receptors for BMPs, such as ActR-II and ActR-IIB, could bind to BMPs.6,33 It is known that ActR-II–deficient mice have mandible development defects, whereas the abnormality is not found in activin-deficient mice.33 In canine mammary gland tumors, the type II receptors other than BMPR-II might also play some role for the stimulation of type I receptor and cartilage formation.

Immunoreactivity for BMP-6 in the interstitial myoepithelial cells tended to be mild compared with those of myoepithelial cells within the basement membrane. Some types of BMPs, such as BMP-2 and BMP-7, are known to induce osteogenesis and psammoma body formation in the presence of type IV collagen that contributes to trapping secreted BMPs.9,15 When BMP-secreting cells are not covered with extracellular matrix, the secreted BMPs are easily hydrolyzed with extracellular protease or dispersed. The connection between myoepithelial cells and basement membrane consisting of type IV collagen may keep levels of BMP-6 high in canine mammary tumors. This phenomenon might also be related to the intense immunoreactivity for BMPRs on the myoepithelial cells within basement membrane.

Interestingly, metaplastic squamous cells showed intense immunoreactivity for both BMPR-IB and BMPR-II. Several previous studies showed that squamous cell carcinomas expressed BMP-2, BMP-5, or BMP-6 (or all).9,29 BMPR-IA and BMPR-IB were detected in the epidermis of mouse embryos.5,33 These findings may indicate the possibility that squamous metaplasia in canine mammary adenocarcinomas is also mediated by BMP signaling through BMPR-IB and BMPR-II. BMP-6 and BMPRs expression also was found in normal mammary gland tissues around the mammary neoplasms. A previous study of mouse mammary gland development has elucidated that mesenchymal and epithelial cells expressed BMP-2 and BMP-4 mRNA temporally and spatially and that these molecules participated in the extension of ducts of mammary gland, which was dependent on epithelial-mesenchymal interaction.23 Extension of mammary ducts also is stimulated by estrogen. It has been reported that BMP-6 synthesis is stimulated by estrogen in vitro.26 Considering these reports and our findings, BMP-6 may act on duct development in both normal and neoplastic canine mammary glands.

In conclusion, this study suggests the participation of BMP-6 signaling through BMPR on primary ectopic cartilage formation in canine mammary tumors. In addition, BMP signaling may mediate mammary development and metaplastic changes including squamous cell metaplasia of glandular epithelium.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wonzny JM: Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87:9843-9847, 1990[Abstract/Free Full Text]
  2. Clement JH, Sanger J, Hoffken K: Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80:250-256, 1999[CrossRef][Web of Science][Medline]
  3. Destexhe E, Lespagnard L, Degeyter M, Heyman R, Coignoul F: Immunohistochemical identification of myoepithelial, epithelial, and connective tissue cells in canine mammary tumors. Vet Pathol 30:146-154, 1993[Abstract]
  4. Dewulf N, Verschueren K, Lonnoy O, Moren A, Grimsby S, Spiegle KV, Miyazono K, Huylebroeck D, Dijke PT: Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic protein during mouse embryogenesis. Endocrinology 136:2652-2663, 1995[Abstract]
  5. Drozdoff V, Wall NA, Pledger WJ: Expression and growth inhibitory effect of decapentaplegic Vg-related protein 6: evidence for a regulatory role in keratinocyte differentiation. Proc Natl Acad Sci USA 91:5528-5532, 1994[Abstract/Free Full Text]
  6. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K, Imamura T: Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112:3519-3527, 1999[Abstract]
  7. Ellis GL, Auclair PL: Atlas of Tumor Pathology. Tumors of the Salivary Glands, 3rd series, vol. 17. AFIP, Washington, DC 1996
  8. Gao T, Lindholm TS, Marttinen A, Urist MR: Composites of bone morphogenetic protein (BMP) and type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics. Int Orthop 20:321-325, 1996[CrossRef][Web of Science][Medline]
  9. Hatakeyama S, Gao YH, Nemoto YO, Kataoka H, Satoh M: Expression of bone morphogenetic proteins of human neoplastic epithelial cells. Biochem Mol Biol Int 42:497-505, 1997[Web of Science][Medline]
  10. Heikinheimo AK, Laine MA, Ritvos OVP, Voutilainen RJ, Hogan LM, Leiro IV: Bone morphogenetic protein-6 is a marker of serous acinar cell differentiation in normal and neoplastic human salivary gland. Cancer Res 59:5815-5821, 1999[Abstract/Free Full Text]
  11. Hughes FJ, Collyer J, Stanfield M, Goodman SA: The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136:2671-2677, 1995[Abstract]
  12. Ishidou Y, Kitajima I, Obama H, Maruyama I, Murata F, Imamura T, Yamada N, Dijke PT, Miyazono K, Sakou T: Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. J Bone Mineral Res 10:1651-1659, 1995[Web of Science][Medline]
  13. Jones CM, Lyons KM, Hogan BL: Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. Development 111:531-542, 1991[Abstract]
  14. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA: Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60:2840-2844, 2000[Abstract/Free Full Text]
  15. Kiyozuka Y, Nakagawa H, Senzaki H, Uemura Y, Adachi S, Teramoto Y, Matsuyama T, Bessho K, Tsubura A: Bone morphogenetic protein-2 and type IV collagen expression in psammoma body forming ovarian cancer. Anticancer Res 21:1723-1730, 2001[Web of Science][Medline]
  16. Kumasa S, Mori H, Mori M, Shibutani T, Iwayama Y, Tsujimura T, Ohnishi T, Arakaki N, Nakata M, Kurisu K: Heterotopic bone formation in tumor stromal tissue: immunohistochemical consideration. Acta Histochem Cytochem 23:427-439, 1990
  17. Kusafuka K, Yamaguchi A, Kayano T, Takemura T: Immunohistochemical localization of the bone morphogenetic protein-6 in salivary pleomorphic adenomas. Pathol Int 49:1023-1027, 1999[CrossRef][Web of Science][Medline]
  18. Lianjia Y, Yan J, Hitoshi N, Shinichiro S, Akihide S, Masahiko M: An immunohistochemical study of bone morphogenetic protein in pleomorphic adenoma of the salivary gland. Virchows Arch A Pathol Anat Histopathol 422:439-443, 1993[CrossRef][Web of Science][Medline]
  19. Liu F, Ventura F, Doody J, Massague J: Human type II receptor for bone morphogenetic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 15:3479-3486, 1995[Abstract]
  20. Lyons K, Graycar JL, Lee A, Hashmi S, Lindguist PB, Chen EY, Hogan BL, Derynck R: Vgr-1, a mammalian gene related to Xenopus Vg-1, is a member of the transforming growth factor beta gene superfamily. Proc Natl Acad Sci USA 86:4554-4558, 1989[Abstract/Free Full Text]
  21. Mehdi R, Shimizu T, Yoshimura Y, Gomyo H, Takaoka K: Expression of bone morphogenetic protein and its receptors in osteosarcoma and malignant fibrous histiocytoma. Jpn J Clin Oncol 30:272-275, 2000[Abstract/Free Full Text]
  22. Misdorp W, Else W, Hellmen E, Lipscomb TP: Histological classification of the mammary tumors of the dog and the cat. World Health Organization International Histological Classification of Tumors of Domestic Animals, second series, vol. 7, pp 1-59, AFIP, Washington, DC 1999
  23. Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clark D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC: Regulation of Mxl-1, Mxl-2, Bmp-2, and Bmp-4 during foetal and postnatal mammary gland development. Development 122:2729-2737, 1996[Abstract]
  24. Rauch F, Lauzier D, Crotheau S, Travers R, Glorieux FH, Hamdy R: Temporal and spatial expression of bone morphogenetic protein-2, -4, and -7 during distraction osteogenesis in rabbits. Bone 27:453-459, 2000[Medline]
  25. Reddi AH: Morphogenetic messages are in the extracellular matrix: biotechnology from bench to bedside. Biochem Soc Trans 28:345-349, 2000[Web of Science][Medline]
  26. Riclard DJ, Hofbauer LC, Bonde SK, Gori F, Spelsberg TC, Riggs BL: Bone morphogenetic protein-6 production in human osteoblastic cell lines: selective regulation by estrogen. J Clin Invest 101:413-422, 1998[Web of Science][Medline]
  27. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, Dijke PT, Heldin CH, Miyazono K: Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 92:7632-7636, 1995[Abstract/Free Full Text]
  28. Soderstrom S, Bengtsson H, Ebendal T: Expression of serine/threonine kinase receptors including the bone morphogenetic factor type II receptor in the developing and adult rat brain. Cell Tissue Res 286:269-279, 1996[CrossRef][Web of Science][Medline]
  29. Sugai T, Oikawa M, Uesugi N, Havano W, Jiao Y, Nakamuura S, Hatakeyama S, Suhara M, Hatafuku K: Esophageal squamous cell carcinoma characterized by extensive chondroid differentiation. Pathol Int 50:514-519, 2000[CrossRef][Web of Science][Medline]
  30. Tateyama S, Uchida K, Hidaka T, Hirao M, Yamaguchi R: Expression of bone morphogenetic protein-6 (BMP-6) in myoepithelial cells in canine mammary gland tumors. Vet Pathol 38:703-709, 2001[Abstract/Free Full Text]
  31. Vos JH, Van den Ingh TS, Misdorp W, Molenbeek RF, Van Mil FN, Rutteman GR, Lvany D, Ramaekers FCS: Immunohistochemistry with keratin, vimentin, desmin, and {alpha}-smooth muscle actin monoclonal antibodies in canine mammary gland: benign mammary tumors and duct ectasias. Vet Q 14:89-95, 1993
  32. Wall NA, Blessing M, Wright CVE, Hogan BLM: Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein. J Cell Biol 120:493-502, 1993[Abstract/Free Full Text]
  33. Yamashita H, Dijke PT, Heldin CH, Miyazono K: Bone morphogenetic protein receptors. Bone 19:569-574, 1996[Medline]
  34. Yang L, Nakamine H, Kamegai A, Sumitomo S, Mori M: Immunohistochemical evaluation of bone morphogenetic protein (BMP) in mixed tumor of skin. J Dermatol Sci 8:96-102, 1994[CrossRef][Medline]
  35. Yoshikawa H, Retting WJ, Takaoka K, Alderman E, Rup B, Rosen V, Wozney JM, Lane JM, Huvos AG, Gorin-Chesa P: Expression of bone morphogenetic proteins in human osteosarcoma: immunohistochemical detection with monoclonal antibody. Cancer 73:85-91, 1994[CrossRef][Web of Science][Medline]
  36. Zhang D, Mehler MF, Song Q, Kessler JA: Development of bone morphogenetic protein receptors in the nervous system and possible roles in regulating trkC expression. J Neurosci 18:3314-3326, 1998[Abstract/Free Full Text]
  37. Zou H, Wieser R, Massague J, Niswander L: Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev 11:2191-2203, 1997[Abstract/Free Full Text]
Request reprints from Dr. S. Tateyama, Department of Veterinary Pathology, Faculty of Agriculture, Miyazaki University, Miyazaki 889-2199, Japan. E-mail: tateyama{at}cc.miyazaki-u.ac.jp.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J. Histochem. Cytochem.Home page
R. Garimella, S. E. Tague, J. Zhang, F. Belibi, N. Nahar, B. H. Sun, K. Insogna, J. Wang, and H. C. Anderson
Expression and Synthesis of Bone Morphogenetic Proteins by Osteoclasts: A Possible Path to Anabolic Bone Remodeling
J. Histochem. Cytochem., June 1, 2008; 56(6): 569 - 577.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akiyoshi, T.
Right arrow Articles by Tateyama, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akiyoshi, T.
Right arrow Articles by Tateyama, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS